A Phase 4 interventional study of Somatropin in Growth Hormone Deficiency, sponsored by Genentech, Inc.. Completed at 33 sites in United States. Open to participants aged 3 Years to 14 Years. Per ClinicalTrials.gov, last updated 2019-01-08.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.
Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 27th largest by enrollment, is one of 3 that started in 2015, is one of 19 in phase 4, and was the 47th registered.
252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.
Browse Dwarfism, Pituitary studies →3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 21–55
Baylor College of Medicine · Sites in United States
Ages 18–64
Changchun GeneScience Pharmaceutical Co., Ltd.
Ages 6 mo–17 yrs
By country, each count listing its studies:
Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 3 Years to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 24 · Phase 4 19
First in 1997; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 82 is above the median of 60 across 169 interventional studies indexed under Dwarfism, Pituitary.
Median enrollment 66 across the 60 interventional studies. Of the 46 that completed or were terminated, 17 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
Hoffmann-La Roche has 4 studies filed under Dwarfism, Pituitary — fewer than ten, so there is no comparison to draw.
2 of the studies testing Human Growth Hormone in Dwarfism, Pituitary that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04867317Phase 3VA Office of Research and DevelopmentGrowth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) | 2027-02-28 |
| NCT05355272Baylor College of MedicineGrowth Hormone Replacement in Veterans With GWI and AGHD (GWIT) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase IV, multicenter, open-label, single-arm study of somatropin (rDNA origin) (Nutropin AQ v1.1) in pre-pubertal children with growth hormone deficiency (GHD) naïve to prior recombinant human growth hormone (rhGH) treatment. The study is designed to characterize the immunogenicity profile of somatropin (rDNA origin) injection when administered daily subcutaneously for 12 months. The clinical impact of immunogenicity will also be assessed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children will receive daily SC injections of somatropin at a dose of up to 0.043 milligrams per kilogram per day (mg/kg/day) for 1 year.
Drug: Somatropin
Somatropin will be administered as SC injections at a dose of up to 0.043 mg/kg/day. The dose may be adjusted for a change in body weight of at least (plus \[+\]/minus \[-\]) 2 kilograms (kg) from baseline at the Month 6 study visit or for a change in insulin-growth factor-1 (IGF-1), as per investigator assessment.
Also known as: Nutropin AQ v1.1
Percentage of Participants Who Develop Anti-GH Antibodies After Treatment With Nutropin AQ v1.1
Participants who were tested positive to anti-GH antibody after initiation of study treatment.
Time frame: Baseline up to 1 year
Percentage of Participants Who Exhibit Functional Growth Attenuation
Growth attenuation is defined as initial growth response greater than pretreatment velocity followed by reduction in growth response to below the pretreatment velocity in the subsequent 6- to 12-month treatment period or reaching ≤ 2 cm per year.
Time frame: Baseline up to 1 year
Percentage of Participants With Neutralizing Antibodies
Among participants who developed positive anti-GH antibody post-baseline, participants who were tested positive to neutralizing anti-GH antibody during study participation.
Time frame: Baseline up to 1 year
Annualized Growth Velocity at Months 6 and 12 (Change From Baseline)
Annualized growth velocity is defined as (height - baseline height) / (date of height assessment - date of baseline)\*365.25. Results are presented according to anti-GH antibody status (positive included all participants that were anti-GH antibody positive at least once post-baseline visit and anti-GH antibody negative population included all participants that were anti-GH antibody negative at all post-baseline visits).
Time frame: Months 6, 12
Height Standard Deviation Score (SDS) at Months 6 and 12 (Change From Baseline)
Height Standard Deviation Score (SDS) allows for the comparison of a participants height to that of others in the same age group. Therefore, the average height for that age group will have the SDS of 0. In this study, the starting Height SDS score was ≤ -1.5 (≤ 5th percentile). Results are presented according to anti-GH antibody status (positive included all participants that were anti-GH antibody positive at least once post-baseline visit and anti-GH antibody negative population included all participants that were anti-GH antibody negative at all post-baseline visits.
Time frame: Months 6, 12
Percentage of Participants With Adverse Events
Among participants who received at least one dose of study drug, those who reported at least one adverse event during study participation.
Time frame: Baseline up to 1 year
| Milestone | Somatropin |
|---|---|
| Started | 82 |
| Modified itt population | 81 |
| Completed | 78 |
| Not completed | 4 |
| Withdrew: Discontinued in error | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 1 |
Participants who were tested positive to anti-GH antibody after initiation of study treatment.
| percentage of participants | Somatropin |
|---|---|
| Percentage of Participants Who Develop Anti-GH Antibodies After Treatment With Nutropin AQ v1.1 | 3.7 (0.77 to 10.44) |
Growth attenuation is defined as initial growth response greater than pretreatment velocity followed by reduction in growth response to below the pretreatment velocity in the subsequent 6- to 12-month treatment period or reaching ≤ 2 cm per year.
| percentage of participants | Somatropin |
|---|---|
| Percentage of Participants Who Exhibit Functional Growth Attenuation | 2.6 (0.31 to 8.96) |
Among participants who developed positive anti-GH antibody post-baseline, participants who were tested positive to neutralizing anti-GH antibody during study participation.
| percentage of participants | Somatropin |
|---|---|
| Percentage of Participants With Neutralizing Antibodies | 0 |
Annualized growth velocity is defined as (height - baseline height) / (date of height assessment - date of baseline)\*365.25. Results are presented according to anti-GH antibody status (positive included all participants that were anti-GH antibody positive at least once post-baseline visit and anti-GH antibody negative population included all participants that were anti-GH antibody negative at all post-baseline visits).
| cm/year | Somatropin |
|---|---|
| 6 months (Anti-GH Antibody Positive) | 5.3 ± 2.89 |
| 6 months (Anti-GH Antibody Negative) | 5.5 ± 2.64 |
| 12 months (Anti-GH Antibody Positive) | 5.2 ± 3.61 |
| 12 months (Anti-GH Antibody Negative) | 4.9 ± 2.40 |
Height Standard Deviation Score (SDS) allows for the comparison of a participants height to that of others in the same age group. Therefore, the average height for that age group will have the SDS of 0. In this study, the starting Height SDS score was ≤ -1.5 (≤ 5th percentile). Results are presented according to anti-GH antibody status (positive included all participants that were anti-GH antibody positive at least once post-baseline visit and anti-GH antibody negative population included all participants that were anti-GH antibody negative at all post-baseline visits.
| SDS | Somatropin |
|---|---|
| 6 months (Anti-GH Antibody Positive) | 0.3 ± 0.11 |
| 6 months (Anti-GH Antibody Negative) | 0.4 ± 0.17 |
| 12 months (Anti-GH Antibody Positive) | 0.8 ± 0.15 |
| 12 months (Anti-GH Antibody Negative) | 0.7 ± 0.25 |
Among participants who received at least one dose of study drug, those who reported at least one adverse event during study participation.
| percentage of participants | Somatropin |
|---|---|
| Percentage of Participants With Adverse Events | 69.5 |
Collected over Adverse events (AEs) were reported from Day 1 until 28 days after last dose of study medication for up to 12 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Somatropin | 0/82 (0%) | 0/82 (0%) | 40/82 (48.8%) |
| Event | Somatropin |
|---|---|
| HeadacheNervous system disorders | 17/82 |
| VomitingGastrointestinal disorders | 12/82 |
| Upper respiratory tract infectionInfections and infestations | 8/82 |
| Injection site bruisingGeneral disorders | 7/82 |
| Pharyngitis streptococcalInfections and infestations | 6/82 |
| RashSkin and subcutaneous tissue disorders | 6/82 |
| PyrexiaGeneral disorders | 5/82 |
| NasopharyngitisInfections and infestations | 5/82 |
| Age, Continuous(years) | Somatropin |
|---|---|
| Mean | 9.0 ± 1.91 |
| Sex: Female, Male(Participants) | Somatropin |
|---|---|
| Female | 17 |
| Male | 65 |
| Ethnicity (NIH/OMB)(Participants) | Somatropin |
|---|---|
| Hispanic or Latino | 11 |
| Not Hispanic or Latino | 70 |
| Unknown or Not Reported | 1 |
| Race/Ethnicity, Customized(participants) | Somatropin |
|---|---|
| Asian | 5 |
| Black or African American | 2 |
| Multiple | 1 |
| Other | 3 |
| Unknown | 3 |
| White | 68 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2015 to primary completion in Nov 2017, 31 months.
Results were first posted in Nov 2018, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone